A Phase 3 Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Alfaelastide Impacts in Patients with Erythropoietic Protoporphyria (EPP)

Project Details

Short titleR:KAE EPP
StatusFinished
Effective start/end date15/03/101/05/11

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.